SproutNews logo

Global Hospital Acquired Disease Testing Market to Reach Worth USD 1.6 Bn by 2022 – Credence Research

According to the latest report published by Credence Research, Inc. “Hospital Acquired Disease Testing Market Growth, Future Prospects and Competitive Analysis, 2016-2022,” the hospital acquired disease testing market was valued at USD 523.0 Mn in 2015, and is expected to reach USD 1,630.0 Mn by 2022, expanding at a CAGR of 5.4% from 2016 to 2022.

Market Insights

Hospital acquired infections/diseases (HAIs) or nosocomial infections are defined to the infection acquired by patients during their stay in healthcare settings. Approximately 9.2 out of 100 patients in the U.S. acquire HAI. The most common types of HAIs include pneumonia, urinary tract infection, bloodstream infection, surgical site infection and others. HAIs are caused by pathogens among patients with compromised immune system, and negligence by hospital staff. The significant morbidity and mortality, the associated management costs and growing pressure from governing bodies have urged care-givers to devise accurate diagnosis of HAIs for efficient healthcare provision.

Browse the full report Hospital Acquired Disease Testing: Market Growth, Future Prospects and Competitive Analysis, 2016-2022 report at http://www.credenceresearch.com/report/hospital-acquired-disease-testing-market

The global hospital acquired disease testing market is categorized into tests for hospital acquired pneumonia, urinary tract infection, surgical site infection, bloodstream infection, MRSA and others. Hospital acquired pneumonia and urinary tract infection together occupy more over 50% market share in 2015 with a larger set of revenue coming from urinary tract infection. The prevalence and morbidity associated with urinary tract infection is the highest among the other infection types and its diagnosis is the swiftest. It is anticipated that the dominance of this segment will continue through the forecast period 2016-2022. Other testing tools for surgical site infections and bloodstream infection are anticipated to undergo faster growth during the forecast period attributed by their alarming incidence in the emerging markets.

Geographically, North America is the largest regional market for hospital acquired disease testing, high number of hospital stays and the corresponding risk of contracting HAIs majorly determine the market size of this region. On the other hand, greater awareness and reducing the incidence of hospital readmission, along with the growing urgency to control hospital and healthcare costs contribute to the faster market growth rate of Asia-Pacific and Latin America hospital acquired disease testing markets.

Browse the full report Hospital Acquired Disease Testing: Market Growth, Future Prospects and Competitive Analysis, 2016-2022 report at http://www.credenceresearch.com/report/hospital-acquired-disease-testing-market

In view of the market competition, this market is fragmented with a multitude of companies offering HAI testing tools. Some of the notable players in the hospital acquired disease testing market include Diatherix Corp, Roche, Cantel Medical Corporation, Qiagen, Cephid, bioMeriux and others.

Latest Reports:

Angina Pectoris Treatment Market By Drug Type (Antiplatelet agents, Beta-adrenergic blocking agents, Calcium channel blockers, Short & Long – acting Nitroglycerines, Angiotensin-converting enzyme inhibitors, Anti-ischemic agents) – Growth, Share, Opportunities & Competitive Analysis, 2015 – 2022

Drug Delivery Technologies Market By Application (Oral, Pulmonary, Transdermal, Injectable, Nasal, Implantable & Others) – Growth, Share, Opportunities & Competitive Analysis, 2015 – 2022

Video Conferencing in Healthcare Market By Deployment Model (On-premise Video Conferencing, Cloud-based Video Conferencing, Managed Video Conferencing Services) – Growth, Share, Opportunities & Competitive Analysis, 2015 – 2022

About Us:

Credence Research is a worldwide market research and counseling firm that serves driving organizations, governments, non-legislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives. Over almost a century, we’ve manufactured a firm extraordinarily prepared to this task.

Who we are

Credence Research is a worldwide firm, containing more than 15 research consultants and almost 100 research and information professionals.

Our customers mirror our worldwide nature. Around 45% are in Europe, 30% in the Americas, 13% in Asia Pacific and 12% in the Middle East and Africa.

Our firm is intended to work as one. We are a solitary global research organization united by a solid arrangement of qualities, concentrated on customer effect.

What we do

We serve customers at each level of their organization, in whatever limit we can be most helpful, whether as a trusted counsel to top management or as a hands-on mentor for forefront representatives. For each engagement, we collect a group with the most suitable experience and ability.

No matter the challenge, we concentrate on delivering functional and persevering results, and preparing our customers to develop and lead. We join forces with customers to place suggestions into practice. Our research specialist work straightforwardly with customers over long stretches to create workforce aptitudes, drive operational change, and apply new working strategies.

Contact:

Name: Chris Smith

Designation: Global Sales Manager

E-mail: sales@credenceresearch.com

Ph: 1-800-361-8290

Web:  Credence Research

 

The post Global Hospital Acquired Disease Testing Market to Reach Worth USD 1.6 Bn by 2022 – Credence Research appeared first on PDF Devices – eReaders and Tablets.

ReleaseID: 3606

Go Top